Sutetinib for Patients with NSCLC Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase IIb Trial. // Journal of Thoracic Oncology. – URL: https://www.sciencedirect.com/science/article/pii/S1556086426006180?dgcid=rss_sd_all
Sutetinib for Patients with NSCLC Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase IIb Trial. Journal of Thoracic Oncology. https://www.sciencedirect.com/science/article/pii/S1556086426006180?dgcid=rss_sd_all
“Sutetinib for Patients with NSCLC Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase IIb Trial.” Journal of Thoracic Oncology.
@article{article117266,
title = {Sutetinib for Patients with NSCLC Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase IIb Trial},
journal = {Journal of Thoracic Oncology},
url = {https://www.sciencedirect.com/science/article/pii/S1556086426006180?dgcid=rss_sd_all}
}
Nature Reviews Cancer, Published online: 19 November 2026; doi:10.1038/s41568-026-01001-2 In this Journal Club, Chien-Han Kao and Ruey-Hwa Chen discuss a study showing that tumours use both de novo purine biosynthesis and purine salvage...
npj Precision Oncology, Published online: 19 November 2026; doi:10.1038/s41698-026-01779-2 Targeting SMYD3 in cancer-associated fibroblasts relieves immune suppression and improves anti-PD-L1 response in HPV-negative HNSCC
npj Precision Oncology, Published online: 19 November 2026; doi:10.1038/s41698-026-01786-3 Postoperative timing effects on AI-based resection-cavity segmentation in glioma: multi-site evaluation and relevance assessment